{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IVT+aflibercept", "query": { "intervention": "IVT aflibercept" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 64, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IVT+aflibercept&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-10T20:11:09.478Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05161806", "title": "Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neovascular Age-related Macular Degeneration (nAMD)" ], "interventions": [ { "name": "SOK583A1 (40 mg/mL)", "type": "DRUG" }, { "name": "Prefilled Syringe (PFS)", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Sandoz", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 30, "start_date": "2022-03-11", "completion_date": "2022-05-04", "has_results": true, "last_update_posted_date": "2022-11-18", "last_synced_at": "2026-09-10T20:11:09.478Z", "location_count": 3, "location_summary": "Marietta, Georgia • Oak Forest, Illinois • Liverpool, New York", "locations": [ { "city": "Marietta", "state": "Georgia" }, { "city": "Oak Forest", "state": "Illinois" }, { "city": "Liverpool", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05161806" }, { "nct_id": "NCT03386474", "title": "Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neovascular Age-related Macular Degeneration" ], "interventions": [ { "name": "Brolucizumab 6 mg", "type": "DRUG" }, { "name": "Aflibercept 2 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 151, "start_date": "2018-01-15", "completion_date": "2018-09-06", "has_results": true, "last_update_posted_date": "2021-01-05", "last_synced_at": "2026-09-10T20:11:09.478Z", "location_count": 63, "location_summary": "Peoria, Arizona • Phoenix, Arizona • Arcadia, California + 56 more", "locations": [ { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Arcadia", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03386474" }, { "nct_id": "NCT02949024", "title": "Suprachoroidal Injection of CLS-TA Alone or With Aflibercept in Subjects With Diabetic Macular Edema", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Diabetic Macular Edema" ], "interventions": [ { "name": "IVT Aflibercept", "type": "DRUG" }, { "name": "SC CLS-TA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Clearside Biomedical, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2016-11-10", "completion_date": "2017-10-17", "has_results": true, "last_update_posted_date": "2021-05-13", "last_synced_at": "2026-09-10T20:11:09.478Z", "location_count": 2, "location_summary": "Mountain View, California • The Woodlands, Texas", "locations": [ { "city": "Mountain View", "state": "California" }, { "city": "The Woodlands", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02949024" }, { "nct_id": "NCT00527423", "title": "Randomized, Single-Masked, Long-Term, Safety and Tolerability Study of VEGF Trap-Eye in AMD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Macular Degeneration" ], "interventions": [ { "name": "VEGF Trap Eye", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 157, "start_date": "2007-08", "completion_date": "2011-10", "has_results": true, "last_update_posted_date": "2013-06-12", "last_synced_at": "2026-09-10T20:11:09.478Z", "location_count": 33, "location_summary": "Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 30 more", "locations": [ { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00527423" }, { "nct_id": "NCT07064759", "title": "Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neovascular Age-Related Macular Degeneration (nAMD)" ], "interventions": [ { "name": "4D-150 IVT (3E10 vg/eye)", "type": "BIOLOGICAL" }, { "name": "EYLEA® (aflibercept) Injection 2 mg (0.05mL)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "4D Molecular Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 480, "start_date": "2025-07-22", "completion_date": "2029-02", "has_results": false, "last_update_posted_date": "2026-04-16", "last_synced_at": "2026-09-10T20:11:09.478Z", "location_count": 54, "location_summary": "Scottsdale, Arizona • Sun City, Arizona • Tucson, Arizona + 49 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Campbell", "state": "California" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07064759" }, { "nct_id": "NCT05704725", "title": "A Study to Evaluate ABP 938 and Aflibercept (Eylea®) in Participants With Chorioretinal Vascular Disease (CVD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chorioretinal Vascular Disease" ], "interventions": [ { "name": "ABP 938", "type": "DRUG" }, { "name": "Aflibercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 49, "start_date": "2023-01-23", "completion_date": "2023-03-24", "has_results": true, "last_update_posted_date": "2025-02-14", "last_synced_at": "2026-09-10T20:11:09.478Z", "location_count": 4, "location_summary": "Austin, Texas • Bellaire, Texas • San Antonio, Texas + 1 more", "locations": [ { "city": "Austin", "state": "Texas" }, { "city": "Bellaire", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" }, { "city": "The Woodlands", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05704725" }, { "nct_id": "NCT07482176", "title": "Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neovascular Age-Related Macular Degeneration (nAMD)", "Wet AMD" ], "interventions": [ { "name": "Ixo-vec", "type": "GENETIC" }, { "name": "Aflibercept", "type": "DRUG" } ], "intervention_types": [ "GENETIC", "DRUG" ], "sponsor": "Adverum Biotechnologies, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 284, "start_date": "2026-03-16", "completion_date": "2031-10-20", "has_results": false, "last_update_posted_date": "2026-07-15", "last_synced_at": "2026-09-10T20:11:09.478Z", "location_count": 79, "location_summary": "Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 65 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT07482176" }, { "nct_id": "NCT03622580", "title": "A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetic Macular Edema" ], "interventions": [ { "name": "Aflibercept", "type": "DRUG" }, { "name": "Faricimab", "type": "DRUG" }, { "name": "Sham Procedure", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 940, "start_date": "2018-09-05", "completion_date": "2021-09-03", "has_results": true, "last_update_posted_date": "2025-07-11", "last_synced_at": "2026-09-10T20:11:09.478Z", "location_count": 85, "location_summary": "Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 78 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Campbell", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03622580" }, { "nct_id": "NCT02299336", "title": "Long-Term Efficacy & Safety of Aflibercept IVT for the Treatment of DME in Subjects Who Completed the VISTA-DME Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetic Macular Edema" ], "interventions": [ { "name": "Aflibercept", "type": "DRUG" }, { "name": "Focal Laser", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Greater Houston Retina Research", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2014-11-24", "completion_date": "2017-01-09", "has_results": true, "last_update_posted_date": "2019-06-04", "last_synced_at": "2026-09-10T20:11:09.478Z", "location_count": 3, "location_summary": "Houston, Texas • Katy, Texas • The Woodlands, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Katy", "state": "Texas" }, { "city": "The Woodlands", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02299336" }, { "nct_id": "NCT06769412", "title": "A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US)", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Retinal Vasculitis" ], "interventions": [ { "name": "aflibercept 2 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 550000, "start_date": "2025-07-01", "completion_date": "2025-09-01", "has_results": false, "last_update_posted_date": "2025-10-29", "last_synced_at": "2026-09-10T20:11:09.478Z", "location_count": 1, "location_summary": "Tarrytown, New York", "locations": [ { "city": "Tarrytown", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06769412" } ] }